5 Breast Cancer Study Results Set to Watch For at ASCO 2026

The American Society of Clinical Oncology (ASCO) annual meeting, happening May 29 to June 2 in Chicago, represents the pinnacle of oncology research, where the world’s leading scientists unveil practice-changing data. For patients with breast cancer, survivors and caregivers, these numbers translate directly into tangible hope: longer remissions, reduced treatment toxicities and smarter, more personalized ways to hit back at both early-stage and advanced disease.

As clinicians gather for the 2026 symposium, the breast cancer track is generating intense buzz. From novel oral hormonal options and potent antibody-drug combinations to a major lifestyle trial, these are five study outcomes that have the potential to rewrite the future of breast cancer care.

1. The lidERA Trial: Oral SERD giredestrant explores its status across menopausal barriers

For individuals with estrogen receptor (ER)-positive, HER2-negative early breast cancer, the most common subtype, the phase 3 lidERA clinical trial is providing vital validation for a highly anticipated oral therapy.

The trial evaluates giredestrant, a selective estrogen receptor degrader (SERD) designed to be taken as a daily pill rather than an injection. Following late-2025 data showing that giredestrant reduced the risk of cancer recurrence or death by 30%, the new ASCO analysis answers a critical clinical question: Does it work equally well regardless of age or hormone status?

2. ASCENT-04: Trodelvy plus Keytruda for triple-negative care

Metastatic triple-negative breast cancer (mTNBC) is historically the most aggressive form of the disease, requiring aggressive treatment strategies out of the gate. The late-breaking primary results of the phase 3 ASCENT-04 trial may offer a potent new blueprint for patients whose tumors express the PD-L1 biomarker.

The trial compared standard front-line chemotherapy plus immunotherapy against a combination: the antibody-drug conjugate Trodelvy (sacituzumab govitecan) paired with the immunotherapy Keytruda (pembrolizumab).

3. SERENA-6: Swapping therapies early may blocks emergent ESR1 resistance mutations

One of the challenges in treating advanced hormone receptor-positive breast cancer is the tumor's ability to mutate and become resistant to initial therapies, frequently via an acquired genetic alteration called an ESR1 mutation. The phase 3 SERENA-6 trial addresses this hurdle head-on with a proactive seek and switch strategy.

Researchers utilized highly sensitive liquid biopsies, blood tests that detect circulating tumor DNA, to spot ESR1 mutations the moment they emerged, before any visible tumor growth appeared on a scan. Patients were then immediately switched from standard aromatase inhibitors to a next-generation oral SERD called camizestrant, while continuing their CDK4/6 inhibitor.

4. The BWEL Trial: The power of targeted weight loss in improving quality of life

Cancer care extends far beyond prescriptions and infusions. The highly anticipated results from the Breast Cancer Weight Loss (BWEL) trial highlight how structured lifestyle interventions can directly mitigate the burdens of survivorship.

The nationwide, randomized phase 3 trial evaluated the impact of a structured weight loss and lifestyle intervention program on women undergoing treatment for breast cancer.

5. The AMBITION Trial: Exploring immunotherapy's reach in HR+/HER2- advanced disease

Hormone receptor-positive (HR+) breast tumors have traditionally been viewed by scientists as "cold" tumors, meaning they do not typically elicit a strong response from the body's immune system, making traditional immunotherapy less effective. The phase 3 JCOG1919E (AMBITION) trial attempts to flip this script.

The study investigated whether adding the immunotherapy agent Tecentriq (atezolizumab) to a backbone of paclitaxel chemotherapy and the anti-angiogenic drug Avastin (bevacizumab) could unlock immune responsiveness in advanced HR+/HER2- disease.

Mechanistically, the chemotherapy induces tumor cell death to release cancer proteins, while the anti-angiogenic drug primes the blood vessels, allowing the immunotherapy to successfully reactivate standard T-cell defenses.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.